Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy

被引：0
作者：
Yoshiaki Nakamura
Takeharu Yamanaka
Keisho Chin
Haruhiko Cho
Hitoshi Katai
Masanori Terashima
Kazunari Misawa
Motohiro Hirao
Kazuhiro Yoshida
Eiji Oki
Mitsuru Sasako
Yasunori Emi
Hideaki Bando
Yoshiyuki Kawashima
Tetsu Fukunaga
Masahiro Gotoh
Takako Ishibashi
Kohei Shitara
机构：
[1] National Cancer Center Hospital East,Department of Gastroenterology and Gastrointestinal Oncology
[2] Yokohama City University,Department of Biostatistics
[3] Cancer Institute Hospital of Japanese Foundation for Cancer Research,Department of Gastroenterology
[4] Kanagawa Cancer Center,Department of Gastrointestinal Surgery
[5] Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital,Department of Surgery
[6] National Cancer Center Hospital,Division of Gastric Surgery
[7] Shizuoka Cancer Center,Division of Gastric Surgery
[8] Aichi Cancer Center Hospital,Department of Gastroenterological Surgery
[9] National Hospital Organization Osaka National Hospital,Department of Surgery
[10] Gifu University,Department of Surgical Oncology, Graduate School of Medicine
[11] Kyushu University Hospital,Department of Surgery and Science, Graduate School of Medical Sciences
[12] Hyogo College of Medicine,Department of Surgery
[13] Saiseikai Fukuoka General Hospital,Department of Surgery
[14] Saitama Cancer Center,Department of Gastroenterological Surgery
[15] St. Marianna University School of Medicine,Department of Gastroenterological and General Surgery
[16] Osaka Medical College,Cancer Chemotherapy Center
[17] Yokohama City University Hospital,Center for Novel and Exploratory Clinical Trials
来源：
Annals of Surgical Oncology | 2019年 / 26卷
关键词：
Capecitabine Plus Oxaliplatin (CAPOX); Survival Outcomes; Gastric Cancer; pStage; Histological Type;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：465 / 472
页数：7
相关论文
共 50 条
  • [21] CYP2A6 Polymorphisms Associate with Outcome of S-1 Plus Oxaliplatin Chemotherapy in Chinese Gastric Cancer Patients
    Lin Yang
    Shanshan Zou
    Chang Shu
    Yan Song
    Yong-Kun Sun
    Wen Zhang
    Aiping Zhou
    Xinghua Yuan
    Yi Yang
    Songnian Hu
    Genomics,Proteomics & Bioinformatics, 2017, (04) : 255 - 262
  • [22] A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial
    Park, S. H.
    Lim, D. H.
    Sohn, T. S.
    Lee, J.
    Zang, D. Y.
    Kim, S. T.
    Kang, J. H.
    Oh, S. Y.
    Hwang, I. G.
    Ji, J. H.
    Shin, D. B.
    Yu, J., I
    Kim, K-M
    An, J. Y.
    Choi, M. G.
    Lee, J. H.
    Kim, S.
    Hong, J. Y.
    Park, J. O.
    Park, Y. S.
    Lim, H. Y.
    Bae, J. M.
    Kang, W. K.
    ANNALS OF ONCOLOGY, 2021, 32 (03) : 368 - 374
  • [23] Long-Term Survival Outcomes of Elderly Patients Treated With S-1 or Capecitabine Plus Oxaliplatin for Stage II or III Gastric Cancer: A Multicenter Cohort Study
    Choi, Seohee
    Min, Jae-Seok
    Jeong, Sang-Ho
    Yoo, Moon-Won
    Son, Young-Gil
    Oh, Sung Jin
    Kim, Jong-Han
    Park, Joong-Min
    Hur, Hoon
    Jee, Ye Seob
    Hwang, Sun-Hwi
    Jin, Sung-Ho
    Lee, Sang Eok
    Lee, Young-Joon
    Seo, Kyung Won
    Park, Sungsoo
    Lee, Chang Min
    Kim, Chang Hyun
    Jeong, In Ho
    Lee, Han Hong
    Choi, Sung Il
    Lee, Sang-Il
    Kim, Chan-Young
    Chae, Hyundong
    Son, Myoung-Won
    Pak, Kyung Ho
    Kim, Sungsoo
    Lee, Moon-Soo
    Kim, Hyoung-Il
    JOURNAL OF GASTRIC CANCER, 2022, 22 (01) : 67 - 77
  • [24] Impact of progression type on overall survival in patients with advanced gastric cancer based on randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin
    Nishikawa, Kazuhiro
    Yamada, Yasuhide
    Ishido, Kenji
    Gotoh, Masahiro
    Bando, Hideaki
    Sugimoto, Naotoshi
    Nishina, Tomohiro
    Amagai, Kenji
    Chin, Keisho
    Niwa, Yasumasa
    Tsuji, Akihito
    Imamura, Hiroshi
    Tsuda, Masahiro
    Yasui, Hirofumi
    Fujii, Hirofumi
    Yamaguchi, Kensei
    Yasui, Hisateru
    Hironaka, Shuichi
    Shimada, Ken
    Miwa, Hiroto
    Hamada, Chikuma
    Hyodo, Ichinosuke
    GASTRIC CANCER, 2017, 20 (04) : 640 - 645
  • [25] Impact of progression type on overall survival in patients with advanced gastric cancer based on randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin
    Kazuhiro Nishikawa
    Yasuhide Yamada
    Kenji Ishido
    Masahiro Gotoh
    Hideaki Bando
    Naotoshi Sugimoto
    Tomohiro Nishina
    Kenji Amagai
    Keisho Chin
    Yasumasa Niwa
    Akihito Tsuji
    Hiroshi Imamura
    Masahiro Tsuda
    Hirofumi Yasui
    Hirofumi Fujii
    Kensei Yamaguchi
    Hisateru Yasui
    Shuichi Hironaka
    Ken Shimada
    Hiroto Miwa
    Chikuma Hamada
    Ichinosuke Hyodo
    Gastric Cancer, 2017, 20 : 640 - 645
  • [26] Long-term Efficacy of S-1 Monotherapy or Capecitabine Plus Oxaliplatin as Adjuvant Chemotherapy for Patients with Stage II or III Gastric Cancer after Curative Gastrectomy: a Propensity Score-Matched Multicenter Cohort Study
    Lee, Chang Min
    Yoo, Moon-Won
    Son, Young-Gil
    Oh, Sung Jin
    Kim, Jong-Han
    Kim, Hyoung-Il
    Park, Joong-Min
    Hur, Hoon
    Jee, Ye Seob
    Hwang, Sun-Hwi
    Jin, Sung-Ho
    Lee, Sang Eok
    Park, Ji-Ho
    Seo, Kyung Won
    Park, Sungsoo
    Kim, Chang Hyun
    Jeong, In Ho
    Lee, Han Hong
    Choi, Sung Il
    Lee, Sang-Il
    Kim, Chan Young
    Kim, In-Hwan
    Son, Myoung-Won
    Pak, Kyung Ho
    Kim, Sungsoo
    Lee, Moon-Soo
    Min, Jae-Seok
    JOURNAL OF GASTRIC CANCER, 2020, 20 (02) : 152 - 164
  • [27] Conversion surgery after S-1 plus oxaliplatin combination chemotherapy for advanced gastric cancer with multiple liver metastases
    Namikawa T.
    Tsuda S.
    Fujisawa K.
    Iwabu J.
    Uemura S.
    Tsujii S.
    Maeda H.
    Kitagawa H.
    Kobayashi M.
    Hanazaki K.
    Clinical Journal of Gastroenterology, 2018, 11 (4) : 297 - 301
  • [28] Health-Related Quality of Life in Patients With Locally Advanced Gastric Cancer Undergoing Perioperative or Postoperative Adjuvant S-1 Plus Oxaliplatin With D2 Gastrectomy: A Propensity Score-Matched Cohort Study
    Yu, Jianhong
    Wang, Zaozao
    Li, Zhexuan
    Liu, Ying
    Fan, Yingcong
    Di, Jiabo
    Cui, Ming
    Xing, Jiadi
    Zhang, Chenghai
    Yang, Hong
    Yao, Zhendan
    Zhang, Nan
    Chen, Lei
    Liu, Maoxing
    Xu, Kai
    Tan, Fei
    Gao, Pin
    Su, Xiangqian
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [29] Comparison of Sinusoidal Obstruction Syndrome in Gastric Cancer Patients Receiving S-1/oxaliplatin Versus Capecitabine/oxaliplatin
    Kim, Eo Jin
    Kim, Moonho
    Seo, Seyoung
    Kim, Mi-jung
    Kim, Min Ju
    Park, Sook Ryun
    ANTICANCER RESEARCH, 2021, 41 (01) : 391 - 402
  • [30] Oxaliplatin plus S-1 or capecitabine as neoadjuvant or adjuvant chemotherapy for locally advanced gastric cancer with D2lymphadenectomy: 5-year follow-up results of a phase II-III randomized trial
    Kan Xue
    Xiangji Ying
    Zhaode Bu
    Aiwen Wu
    Zhongwu Li
    Lei Tang
    Lianhai Zhang
    Yan Zhang
    Ziyu Li
    Jiafu Ji
    Chinese Journal of Cancer Research, 2018, 30 (05) : 516 - 525
12345